Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
MARLBOROUGH, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company, today announced that it will release financial results for the first quarter of
GlobeNewswireApr 22 16:05 ET
Piper Sandler Keeps Their Buy Rating on Akoya Biosciences (AKYA)
TipRanksApr 9 07:06 ET
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting With Case Studies Demonstrating Unprecedented Speed and Scale
MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company, today announced it will highlight case studies featuring its Spatial Biol
GlobeNewswireApr 5 08:00 ET
Akoya Biosciences(AKYA.US) Officer Sells US$37,242.75 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 20, 2024 at an average price of $4.9657 for a total value of $37,242.75.Source: Announcement What is sta
moomoo NewsMar 22 18:36 ET
(SEC Amendment) Akoya Biosciences(AKYA.US) Officer Sells US$37,042.5 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 13, 2024 at an average price of $4.939 for a total value of $37,042.5.Source: Announcement What is state
moomoo NewsMar 22 18:31 ET
Akoya Biosciences Names BostonGene as a Qualified CRO Service Provider
Bringing End-to-End Spatial Biology Solutions to Life Sciences Researchers for Advanced Spatial Proteomics AnalysisWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-driven molecula
BusinesswireMar 19 07:00 ET
Akoya Biosciences(AKYA.US) Officer Sells US$37,035 in Common Stocks
$Akoya Biosciences(AKYA.US)$ Officer McKelligon Brian sold 7,500 shares of Common Stocks on Mar 13, 2024 at an average price of $4.938 for a total value of $37,035.Source: Announcement What is stateme
moomoo NewsMar 14 21:23 ET
Akoya Biosciences (AKYA) Gets a Buy From Piper Sandler
TipRanksMar 12 06:36 ET
Akoya Biosciences, Inc.'s (NASDAQ:AKYA) Market Cap Dropped US$62m Last Week; Individual Investors Who Hold 49% Were Hit as Were Institutions
Key Insights The considerable ownership by private equity firms in Akoya Biosciences indicates that they collectively have a greater say in management and business strategy 53% of the business is he
Simply Wall StMar 8 05:45 ET
Akoya Biosciences Is Maintained at Overweight by JP Morgan
Akoya Biosciences Is Maintained at Overweight by JP Morgan
Dow JonesMar 6 11:16 ET
Express News | JP Morgan Maintains Overweight on Akoya Biosciences, Lowers Price Target to $10
Moomoo 24/7Mar 6 11:06 ET
Akoya Biosciences Price Target Raised to $7.50/Share From $7.00 by UBS
Akoya Biosciences Price Target Raised to $7.50/Share From $7.00 by UBS
Dow JonesMar 5 09:54 ET
Akoya Biosciences Is Maintained at Buy by UBS
Akoya Biosciences Is Maintained at Buy by UBS
Dow JonesMar 5 09:54 ET
Express News | Canaccord Genuity Reiterates Buy on Akoya Biosciences, Maintains $10 Price Target
Moomoo 24/7Mar 5 08:58 ET
Akoya Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 75.44% Canaccord Genuity → $10 Reiterates Buy → Buy 12/14/2023 — Guggenheim Initiates Coverage
BenzingaMar 5 08:56 ET
Earnings Call Summary | Akoya Biosciences(AKYA.US) Q4 2023 Earnings Conference
The following is a summary of the Akoya Biosciences, Inc. (AKYA) Q4 2023 Earnings Call Transcript:Financial Performance:Akoya's Q4 2023 revenue hit $26.5 million and yearly revenue closed at $96.6 mil
moomoo AIMar 4 21:06 ET · Conference Call
Akoya Biosciences Inc (AKYA) Reports Record Q4 Revenue and Sets Positive 2024 Outlook
Yahoo FinanceMar 4 17:31 ET
Recap: Akoya Biosciences Q4 Earnings
Akoya Biosciences (NASDAQ:AKYA) reported its Q4 earnings results on Monday, March 4, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsAkoya Biosciences beat estimated
BenzingaMar 4 16:15 ET
Akoya Biosciences GAAP EPS of -$0.22 Beats by $0.06, Revenue of $26.5M Beats by $0.39M
Seeking AlphaMar 4 16:13 ET
Akoya Biosciences Sees 2024 Rev $114M-$118M >AKYA
Akoya Biosciences Sees 2024 Rev $114M-$118M >AKYA
Dow JonesMar 4 16:07 ET
No Data
No Data